X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
neurology (40) 40
alzheimer's disease (35) 35
humans (27) 27
index medicus (25) 25
immunotherapy (23) 23
female (21) 21
male (20) 20
neurosciences (19) 19
aged (17) 17
clinical neurology (15) 15
brain (14) 14
middle aged (13) 13
alzheimer disease - drug therapy (12) 12
clinical trials (11) 11
article (10) 10
magnetic resonance imaging (9) 9
aged, 80 and over (8) 8
cognition (8) 8
dementia (8) 8
analysis (7) 7
antibodies, monoclonal, humanized - therapeutic use (7) 7
biomarkers (7) 7
treatment outcome (7) 7
alzheimer disease (6) 6
alzheimer disease - genetics (6) 6
alzheimers disease (6) 6
bapineuzumab (6) 6
care and treatment (6) 6
cerebrospinal fluid (6) 6
double-blind method (6) 6
imaging abnormalities (6) 6
mild cognitive impairment (6) 6
neuroimaging (6) 6
safety (6) 6
severity of illness index (6) 6
studies (6) 6
united states (6) 6
alzheimer disease - cerebrospinal fluid (5) 5
alzheimers-disease (5) 5
amyloid (5) 5
amyloid beta-protein (5) 5
animals (5) 5
biological markers (5) 5
biomarker (5) 5
brain - pathology (5) 5
diagnostic imaging (5) 5
longitudinal studies (5) 5
mri (5) 5
tau (5) 5
trials (5) 5
alzheimer disease - diagnosis (4) 4
alzheimer disease - diagnostic imaging (4) 4
alzheimer disease - pathology (4) 4
amyloid-beta (4) 4
antibodies (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
atrophy (4) 4
dose-response relationship, drug (4) 4
drug therapy (4) 4
edema (4) 4
genetic aspects (4) 4
monoclonal antibodies (4) 4
multidisciplinary sciences (4) 4
neurodegenerative diseases (4) 4
neuroimaging - methods (4) 4
neurovetenskaper (4) 4
patients (4) 4
research (4) 4
a-beta (3) 3
alzheimer disease - metabolism (3) 3
amyloid beta-peptides (3) 3
amyloid beta-peptides - blood (3) 3
amyloid beta-peptides - metabolism (3) 3
amyloid pet (3) 3
amyloid plaques (3) 3
amyloidosis (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
biomarkers - cerebrospinal fluid (3) 3
brain - drug effects (3) 3
brain - metabolism (3) 3
brain - physiopathology (3) 3
brain volume (3) 3
cerebral microbleeds (3) 3
cognitive ability (3) 3
cognitive neuroscience (3) 3
cohort studies (3) 3
development and progression (3) 3
diagnosis (3) 3
genetic variation (3) 3
genetics (3) 3
genome-wide association study (3) 3
health aspects (3) 3
mci (3) 3
medical colleges (3) 3
medical research (3) 3
medicine, experimental (3) 3
monoclonal (3) 3
neuropsychological tests (3) 3
nuclear magnetic resonance--nmr (3) 3
pathology (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 4, pp. 322 - 333
In two phase 3 trials in patients with Alzheimer's disease, bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, did not improve clinical outcomes.... 
ANTIBODIES | MEDICINE, GENERAL & INTERNAL | EPITOPE | IMAGING ABNORMALITIES | PEPTIDE | MOUSE MODEL | Phosphorylation | Humans | Middle Aged | Male | Positron-Emission Tomography | Treatment Failure | Aged, 80 and over | Amyloid beta-Peptides - cerebrospinal fluid | Female | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Biomarkers - analysis | Alzheimer Disease - drug therapy | tau Proteins - cerebrospinal fluid | Alzheimer Disease - cerebrospinal fluid | Cognition - drug effects | Neuropsychological Tests | Amyloid beta-Peptides - antagonists & inhibitors | Apolipoproteins E - genetics | Intention to Treat Analysis | Amyloid beta-Peptides - analysis | Brain - pathology | Aged | Biomarkers - cerebrospinal fluid | Edema - chemically induced | Alzheimer Disease - genetics | Monoclonal antibodies | Product development | Research | Drug therapy | Alzheimer's disease | Health aspects | Edema | Nuclear magnetic resonance--NMR | Intravenous administration | Neurodegenerative diseases | Cognitive ability | Clinical trials | Cerebrospinal fluid | Patients | Studies | Tau protein | Apolipoprotein E | Immunotherapy | Alleles | Dementia disorders | Alzheimers disease | Index Medicus | Abridged Index Medicus | Brain | Neurosciences | pathology | Biological Markers | Antibodies | Cognition | tau Proteins | 80 and over | genetics | Amyloid beta-Peptides | Apolipoproteins E | Monoclonal | Neurovetenskaper | drug therapy | chemically induced | Humanized | drug effects | Alzheimer Disease | analysis | antagonists & inhibitors | cerebrospinal fluid | adverse effects | therapeutic use
Journal Article
2019, ISBN 9780128031612, Volume 29
Alzheimer's Disease Neuroimaging Initiative (ADNI) began as a 5-year research project launched in 2004 through a public-private partnership with public funding... 
ADNI | Biomarkers | PET imaging | LONI | AD pathology | Fluid biomarkers
Book Chapter
Lancet Neurology, ISSN 1474-4422, 2012, Volume 11, Issue 3, pp. 241 - 249
Journal Article
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, ISSN 1552-5260, 04/2018, Volume 14, Issue 4, pp. 535 - 562
Journal Article